[Deterioration of liver function following endoscopic injection sclerotherapy of esophageal varices--significance of a new index for liver function "delta TB"].
Changes of liver functions associated with endoscopic injection sclerotherapy (EIS) in which less than 6 ml of 5% ethanolamin oleate was used were investigated in 50 patients with remarkable esophageal varices. The index used for evaluating hepatic reserve was the difference of total bilirubin in serum between immediately and 15 hours after EIS and was tentatively named as "delta TB" (normal range < or = 0.1). In the patients classified as Child-Pugh A (n = 25), Child-Pugh B (n = 19) and Child-Pugh C (n = 6), delta TB was 0.04 +/- 0.30, 0.23 +/- 0.41, and 0.54 +/- 0.21, respectively. One month after the entire sessions of EIS, the changes of liver function tests before and after EIS were compared in 45 cases. It was disclosed that delta TB was elevated in parallel with the severity of their liver dysfunction before EIS. Also, delta TB seems to reflect the prognosis of the patients treated by EIS for some extent, since the survival period of the cases treated by EIS were correlative with delta TB (r = -0.734, p < 0.01), and delta TB of 20 cases who survived for longer than 5 years after EIS was 0.04 +/- 0.32. Therefore, delta TB seems to be a useful marker for estimating the influence of EIS on liver function.
Matsumoto
H
H
Department of Gastroenterology, Toshiba Hospital.
Suzuki
F
F
Souda
K
K
Kitahara
H
H
Kobayashi
Y
Y
Tsugiki
M
M
Kawasaki
T
T
Nakao
K
K
Matsumoto
M
M
Iwata
K
K
D000328:Adult; D000368:Aged; D001663:Bilirubin / Q000097:blood*; D004932:Esophageal and Gastric Varices / Q000503:physiopathology / Q000628:therapy*; D004945:Esophagoscopy; D005260:Female; D006801:Humans; D007267:Injections / Q000379:methods; D008099:Liver / Q000503:physiopathology*; D008111:Liver Function Tests / Q000379:methods; D008297:Male; D008875:Middle Aged; D009829:Oleic Acids / Q000008:administration & dosage / Q000009:adverse effects; D012597:Sclerosing Solutions / Q000008:administration & dosage / Q000009:adverse effects; D015911:Sclerotherapy / Q000009:adverse effects*
D009829:Oleic Acids; D012597:Sclerosing Solutions; D001663:Bilirubin; C033343:ethanolamine oleate